Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage
- Date 15 Sep 2020
Vectura announces that it has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS), to develop inhaled oxytocin delivered via a dry powder inhaler to prevent postpartum haemorrhage (PPH) in childbirth.
An inhaled formulation of oxytocin, currently administered via injection, is expected to provide important advantages including ease of use, rapid onset of action and safe storage outside of the cold chain. Vectura will receive undisclosed revenues on a fee-for-service basis.
You might also be interested in these articles
Steaming up Success: ARU student’s path from café to creativity
We recently did a Q&A session with Anglia Ruskin student Soorya Jith, who started his journey as a Barista at the Lakeside Café within the Bradfield Centre on Cambridge Science Park. He has now transitioned to Krank, also located on the Park, as a Junior Graphic Designer.
Sun 21 Apr 2024
Cambridge Science Park
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
Xampla welcomes former P&G chemist to team as scale-up accelerates
accelerates CREATOR of plastic-free, natural materials, Xampla, continues to scale-up the commercialisation of its biodegradable Morro materials with new industry hire.
Fri 1 Mar 2024
Xampla Ltd
